Skip to main content
Journal of Genetic Engineering and Biotechnology
Fig. 1 | Journal of Genetic Engineering and Biotechnology

Fig. 1

From: IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

Fig. 1

IL28B rs12979860 single-nucleotide polymorphism is linked to virologic response after treatment with direct-acting antiviral plus pegylated interferon/ribavirin. All patients (100%) with CC genotype achieved HCV-RNA < 25 IU/ml response after treatment with SOF/RBV with and without Peg-INF. In return, T allele carriers achieved HCV-RNA < 25 IU/ml response in A 84.5% after treatment with SOF/RBV and B 85.6% after treatment with SOF/RBV + Peg-INF. Administration of zinc improved virologic response after treatment with both C SOF/RBV and D SOF/RBV + Peg-INF. IL-28B rs12979860 single-nucleotide polymorphism genotypes. T allele carriers = CT/TT combined

Back to article page